Carisma Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CARM research report →
Range $6 – $6
Price Chart
About the company
Carisma Therapeutics, Inc. , a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis.
- CEO
- Craig R. Jalbert
- IPO
- 2014
- Employees
- 46
- HQ
- Philadelphia, PA, US
Get TickerSpark's AI analysis on CARM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $20.92K
- P/E
- 0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -0.02
- EV/EBITDA
- -0.05
- Div Yield
- 0.00%
- Gross Margin
- 99.21%
- Op Margin
- 84.06%
- Net Margin
- 77.22%
- ROE
- -149.10%
- ROIC
- -36224.76%
Latest fiscal year · YoY change
- Revenue
- $19.63M+31.6%
- Gross Profit
- $-40,041,000+32.4%
- Op Income
- $-62,179,000
- Net Income
- $-60,477,000+30.4%
- EPS
- $-1.46+43.6%
- OCF Growth
- +26.2%
- FCF Growth
- +27.1%
- 52W High
- $0.29
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.02
- Beta
- -9.60
- RSI (14)
- 36
- Avg Volume
- 9.00K
No earnings-call transcripts are available for CARM yet.
- Free Float
- 72.0%
- Shares Outstanding
- 41.85M
- Float Shares
- 30.14M
of shares held by institutions
3 13F filers
Buy/sell ratio 0.20. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Union Bancaire Privee, Ubp SA | 785 | 0 |
| Org Partners LLC | 200 | 0 |
Held by 30 ETFs
Biggest fund positions in CARM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 7, 25 | Klichinsky Michael | other | 56,982 |
| Oct 7, 25 | Klichinsky Michael | sell | 56,982 |
| Oct 7, 25 | Klichinsky Michael | other | 56,982 |
| Oct 1, 25 | Klichinsky Michael | sell | 165,000 |
| Oct 2, 25 | Klichinsky Michael | sell | 200,000 |
| Oct 3, 25 | Klichinsky Michael | sell | 119,347 |
| Jan 28, 25 | Klichinsky Michael | other | 221,000 |
| Jan 28, 25 | Kelly Steven | other | 500,000 |
| Jan 1, 25 | McAndrew Natalie | other | 0 |
| Oct 31, 24 | Cheng Sohanya Roshan | other | 38,700 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CARM coverage
Recent articles, reports, and earnings notes.
No research on CARM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CARM report →Carmila: 2026 H1 Results
businesswire.com · Jul 29
Critical Review: Carisma Therapeutics (NASDAQ:CARM) vs. Protalex (OTCMKTS:PRTX)
defenseworld.net · Apr 14
Carmila: 2025 Annual Results
businesswire.com · Feb 18
Financial Comparison: Context Therapeutics (NASDAQ:CNTX) vs. Carisma Therapeutics (NASDAQ:CARM)
defenseworld.net · Feb 5
Carisma Announces Delisting from Nasdaq and SEC Deregistration
prnewswire.com · Dec 5
Head-To-Head Survey: Achieve Life Sciences (NASDAQ:ACHV) vs. Carisma Therapeutics (NASDAQ:CARM)
defenseworld.net · Nov 23
Carmanah Minerals Engages Warrior Drilling for Heritage Project; Targets Historic Eagle Zone on Burin Trend, NL
feeds.newsfilecorp.com · Nov 6
Comparing Cassava Sciences (NASDAQ:SAVA) and Carisma Therapeutics (NASDAQ:CARM)
defenseworld.net · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.